This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 21.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 21.75 Contact Hours.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is eligible for ACPE credit; see final CPE activity announcement for specific details.
Acknowledgement of Commercial Support
This activity is supported by educational grants from AstraZeneca, Boehringer Ingeheim Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Inc., Exelixis, Ignyta, Incyte Corporation, Ipsen Biopharmaceuticals, Inc., Lilly, Novartis Pharmaceuticals Corporation, Novocure, Pharmacyclics LLC, an AbbVie Company, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, Taiho Oncology, and Takeda Oncology.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
35th Annual CFS®
Wednesday, November 8, 2017 – Friday, November 10, 2017
New York Marriott Marquis
New York, NY 10036
(800) 843-4898 | Book Online
Providing state-of-the-art cancer care through diagnostic, therapeutic, and supportive strategies is dependent on incorporating the latest clinical advancements and data into practice. In solid tumors and hematologic malignancies alike—and across all cancer types—novel approaches in testing, systemic therapy, targeted and immunotherapies, and combination strategies continue to drive improvements in patient outcomes.
Now in its 35th year, the Chemotherapy Foundation Symposium™ (CFS™) brings together more than 2000 healthcare professionals, including oncologists, hematologists, radiologists, immunologists, pharmacists, NPs, PAs, and patient advocates, and strives to deliver the latest answers to your clinical challenges. Our internationally renowned faculty will provide expert analysis on the most recent developments in cancer therapies, synthesizing scores of data to provide attendees with the critical distilled information they need. This preeminent 3-day conference provides an unparalleled opportunity to learn new methods of personalizing care for your patients with cancer. Together, we will Innovate Cancer Therapy for Tomorrow®. See you in New York!
Acknowledgement of Commercial Support
This activity is supported by educational grants from AstraZeneca, Boehringer Ingeheim Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Inc., Exelixis, Ignyta, Incyte Corporation, Ipsen Biopharmaceuticals, Inc., Lilly, Novartis Pharmaceuticals Corporation, Novocure, Pharmacyclics LLC, an AbbVie Company, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, Taiho Oncology, and Takeda Oncology.Target Audience
This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend.
Upon completion of this activity, participants should be better prepared to:
- Determine the most appropriate testing strategies to stratify risk and inform clinical decision-making in the management of cancer
- Describe important clinical trial results that inform treatment practices and are altering care paradigms for patients with hematologic malignancies and solid tumors
- Identify immunotherapeutic, chemotherapeutic, and targeted approaches demonstrated by recent evidence to optimize clinical outcomes
- Delineate methods multidisciplinary teams can proactively apply to prevent and mitigate the impact of treatment-related toxicities findings in the context of evolving treatment pathways to improve care for patients with cancer
- Assess practice-changing evidence and apply these findings in the context of evolving treatment paradigms to optimize the care of patients with cancer
2017 Hot Topics
- Immunotherapies and Their Latest Applications in Cancer, Including Combinations
- Harnessing the Latest Technologies, Biomarkers, and Tests to Optimize Clinical Decision Making
- Microsatellite Instability‒Guided Care Across Multiple Tumor Types
- How to Maximize Outcomes in Multiple Myeloma
- Factoring MRD Into Treatment Plans for Patients With Hematologic Malignancies
- Tackling Clinical Challenges in the Management of Myeloproliferative Neoplasms
- Practice-Changing Paradigms in Acute Leukemias
- Providing State-of-the-Art Care for Older Patients With Hematologic Malignancies
- Coming Soon to Your Clinic: Evolving Strategies for Hepatocellular Carcinoma, Pancreatic Cancer, and Gastric Cancer
- Options and Considerations for Metastatic Colorectal Cancer in the Frontline and Beyond Progression
- Progress in Soft-Tissue Sarcoma and Non‒Soft-Tissue Sarcoma
- Ovarian Cancer: PARP Inhibition, Maintenance Strategies, Immunotherapy, Angiogenesis Targeting, and Clinical Trial Designs
- Novel Therapeutic Approaches in Breast Cancer Treatment: Immunotherapy and Combinations
- Treatment Planning for Early, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Considerations
- Individualized Care for Patients With Advanced Triple-Negative Breast Cancer
- Precision Care for Patients With Non-Small Cell and Small Cell Lung Cancer
- Bladder Cancer: More Options, More Clinical Considerations
- New Horizons in Prostate Cancer: Expert Sequencing, Targeting DNA Repair Deficiency, and Immunotherapy
- Updates in Glioblastoma: Technologies, Targeted Therapy, and Immunotherapy
- Optimizing Your Patients’ Quality of Life: Focus on CINV, Sexuality, and Palliation
- Advances in Melanoma and Nonmelanoma Carcinomas
- Cancer-Associated Cardiomyopathy: Web-Based Diagnostic and Management Technologies
- Moon Shots Program™ Update
And much more!
Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/ Oncology
Co-Director, Comprehensive Breast Cancer Center Associate
Director, Clinical Investigation
University of Pittsburgh
Benjamin Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
William Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, NY
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.